Cancer Risk Blood Test for Men – Basic (6 Biomarkers)

The Cancer Risk Blood Test for Men (Basic) is a five-marker screening panel designed for men who want an objective baseline picture of their cancer risk profile. It brings together the most widely used circulating tumour markers for colorectal, liver, pancreatic, biliary and prostate disease in a single blood sample, giving you and your doctor a structured starting point for further discussion. It is suited to men with a family history of cancer, men over 45 who have not recently reviewed their health, men with persistent unexplained symptoms such as changes in bowel habit, abdominal discomfort, jaundice or urinary disturbance, and men who simply want a documented baseline to compare against in future years.

General and gastrointestinal tumour markers

• Carcinoembryonic antigen (CEA): the most established marker associated with colorectal cancer, also raised in pancreatic, gastric, lung and thyroid tumours, and in benign conditions such as smoking, inflammation and liver disease.
• Alpha-fetoprotein (AFP): primarily associated with primary liver (hepatocellular) cancer and non-seminomatous germ cell tumours of the testis, and also elevated in chronic liver disease and hepatitis.
• Carbohydrate antigen 19-9 (CA 19-9): associated with pancreatic and biliary tract cancers, and also raised in colorectal, gastric and liver disease as well as benign biliary obstruction and pancreatitis.

Prostate markers

• Total PSA: the total amount of prostate-specific antigen circulating in the blood, which can rise with prostate cancer, benign prostatic enlargement, prostatitis and recent ejaculation or vigorous exercise.
• Free PSA: the proportion of PSA circulating unbound to carrier proteins, which helps your doctor interpret a raised total PSA more precisely.
• PSA ratio: the calculated free-to-total PSA ratio, a refinement that adds useful context when total PSA sits in the borderline range.

Tumour markers are proteins that can be produced by cancer cells, but they can also rise in entirely benign conditions. No marker in this panel can confirm or exclude a cancer on its own, so results are most meaningful when reviewed by your doctor alongside your medical history, symptoms, examination findings and any imaging or referral decisions. This panel is a screening and monitoring aid, not a stand-alone diagnosis.

Why it matters

Cancer found earlier is generally easier to treat, and yet many cancers of the bowel, liver, pancreas and prostate produce no obvious symptoms until they are advanced. Measuring these five markers together gives you a documented, reproducible baseline that your doctor can act on: it can prompt a timely referral, support a decision to investigate further, or provide reassurance when results sit comfortably within range. Just as importantly, a stored baseline allows genuine comparison over time, so any future change is spotted against your own normal rather than a generic reference range. For men with a family history or ongoing symptoms, it turns vague concern into concrete clinical information you can discuss at your next appointment.